The impact of the gsp oncogene on the expression of genes engaged in the somatotroph cell phenotype remains poorly understood in human somatotroph adenomas. As the gsp oncogene is associated with an increased octreotide (somatostatin agonist) sensitivity, a group of 8 somatotroph adenomas bearing the gsp mutation (gspϩ) and another group of 16 adenomas without the mutation (gspϪ) were analyzed, all of them presenting variable octreotide sensitivities. The expressions of genes encoding for G s ␣, Pit-1, G i2 ␣, and SSTR2, involved in the regulation of secretory activity in somatotroph cells, were assessed by Northern blot. A decreased expression of the G s ␣ gene was found in gspϩ tumors, suggesting the existence of a negative feedback of the oncogenic protein upon its own messenger ribonucleic acid (mRNA). In contrast, G i2 ␣, Pit-1, and GH messengers were not significantly different in the groups. A positive correlation between the in vitro and in vivo GH octreotide-induced secretory inhibition and the expression of SSTR2 mRNA was found. However, the expression of the gene for SSTR2 appeared not to be different between gspϩ and gspϪ, even when the octreotide sensitivity was significantly higher in the adenomas carrying the mutation. Interestingly, the SSTR2 gene expression was significantly correlated to those of G i2 ␣ and Pit-1. In the same way, the G s ␣ mRNA expression was positively correlated with those of G i2 ␣ and Pit-1. Such correlations strongly suggest a concerted dysregulation of the expression of these genes in both categories of adenomas. The loss of the octreotide sensitivity represents one aspect of the dysregulation process that partially results from the decreased SSTR2 expression. However, the improvement of the sensitivity associated with the presence of the gsp oncogene seems to proceed in a way different from SSTR2 expression. (J Clin Endocrinol
H UMAN pituitary adenomas are considered monoclonal in origin (1, 2) . This condition opens the possibility that somatic mutations could be involved in the oncogenetic process. When the repertory of known oncogenes is examined in connection with somatotroph adenomas, the only oncogene consistently found is the gsp oncogene, detected in about 30 -40% of the tumors (3) (4) (5) (6) . The gsp oncogene results from point mutations localized at codons 201 and 227, which are two critical sites involved in the intrinsic guanosine triphosphatase activity of the G s ␣ protein, thus leading to a constitutive activation of the adenyl cyclase (7) . Several studies failed to determine a clinical specific phenotype related to the gsp mutation (4 -6, 8, 9) . In the GH 3 or GC pituitary cell line, an impact of the gsp oncogene on the expression of genes coding for the transcription factor Pit-1 and for GH has been demonstrated (9 -11) . However, the impact of gsp oncogene on gene expressions is still poorly understood in human adenomas.
GH hypersecretion present in somatotroph adenomas can be inhibited by somatostatin agonists such as octreotide or lanreotide. Awkwardly, serum GH and insulin-like growth factor I levels reach normal values in only 50% of treated patients (12) . The molecular mechanisms controlling somatostatin sensitivity are incompletely understood. Some studies have suggested that tumors with the gsp oncogene (8, 9, 13) or with high adenylate cyclase activity (14) displayed a better sensitivity to somatostatin. In fact, we have shown that the G s ␣ mutation could be a marker of the susceptibility of the tumor to be controlled by octreotide (6) . The mechanisms by which the gsp oncogene improves sensitivity have not been identified, although the expression of somatostatin receptor (SSTR) could play an important role. It is well known that the resistance to dopamine agonists in prolactinomas is partially due to a decreased expression of the D2 receptor (15, 16) . Moreover, in dopamine-resistant prolactinomas, decreased expressions of the messengers for Pit-1 and G i2 ␣ were observed (16, 17) ; both proteins are involved in the dopaminergic transduction pathway. It is therefore likely that the same type of alteration could be responsible for somatostatin unresponsiveness in somatotroph adenomas. The two somatostatin agonists preferentially employed in acromegaly, octreotide and lanreotide, display a higher affinity for the SSTR2 subtype. In addition, postreceptor anomalies touching proteins involved in SSTR2 transduction pathways, such as G i2 ␣ and Pit-1 (for review, see Ref. 18) , may also contribute to the somatostatin unresponsiveness.
In the present study, a series of 24 somatotroph adenomas presenting with variable sensitivity to octreotide and bearing, or not, the gsp oncogene was compared. Our first aim was to examine the impact of gsp oncogene on the expression of the genes coding for G s ␣, G i2 ␣, Pit-1, and SSTR2. Secondly, we asked whether changes in the expression of some of these genes could alter the sensitivity to octreotide. In this study, a lower expression of G s ␣ gene in gspϩ tumors was found. The decreased sensitivity to the somatostatin agonist was shown to be related at least in part to a lower expression of the SSTR2 gene. However, this expression was not higher in the gspϩ group. Finally, we found a coordinated decrease in the expression of the genes coding for all those proteins; all of them were implicated in the differentiation and the regulation of secretory activity of somatotroph cells.
Subjects and Methods

Patients and clinical assessment
The present study was approved by the ethics committee of the University of Aix-Marseille (France) and was undertaken after informed consent was obtained from each patient and all participants. Twentyfour acromegalic patients, aged 24 -67 yr, were selected. The endocrine status and the characterization of the tumors were determined previous to treatment (Table 1) . The basal GH and PRL levels were measured using commercial kits (Immunotech, Marseilles, France; Medgenix Diagnosis, Fleurus, Belgium) and expressed as the mean GH or PRL plasma levels obtained hourly for 6 h. Sizes and extent of pituitary tumors were evaluated by magnetic resonance imaging. The evaluation of in vivo octreotide sensitivity was performed as follows. After a single 100-g sc injection of octreotide (Sandostatin, Novartis, Basel, Switzerland), blood samples were withdrawn every hour for 6 h to measure GH plasma concentrations. The GH inhibition was represented by the difference between basal GH values and the mean GH levels between 2-6 h after administration of the drug and was reported as a percentage of the basal level.
Methods
Immediately after transphenoidal ablation, each tumor was collected and divided into three parts: one was used for immunocytochemical analysis, another was used for cell culture, and the third was frozen at Ϫ80 C for subsequent detection of gsp mutations and quantification of G s ␣, G i2 ␣, Pit-1, SSTR2, and GH messenger ribonucleic acids (mRNAs). The methods for histopathological analyses have been previously described (6). The immunostaining was positive for GH in all tumors and for PRL and ␣-subunit glycoprotein in some of them (Table 1 ) and was negative for FSH␤, LH␤, TSH␤, and ACTH in all of them. Those tumors previously found to contain labeled cells for FSH␤, LH␤, TSH␤, and ACTH were excluded from the series presented here. 
Detection of G s ␣ mutations
Total RNA extraction, RT-PCR amplification of G s ␣, and direct sequence analysis of the G s ␣ PCR product were performed on each tumoral fragment for identification of the gsp mutation (for details, see Ref. 6) . Eight adenomas presented the mutation. In all cases, Arg was substituted for Cys, reflecting a CGT to TGT mutation.
Cell culture studies
After mechanical and enzymatic dissociation, 3-5 ϫ 10 5 cells were plated on coated culture wells (19) . Cells were cultured in serum-free medium for 24 h with or without a maximal (10 Ϫ8 mol/L) concentration of octreotide. The culture media were then collected and stored frozen for GH measurement (6) . The effects of the drug were tested in quadruplicate.
Northern blot analysis
Northern blot were performed using 20 g total RNA (20) . The G s ␣, G i2 ␣, Pit-1, SSTR2, and GH mRNAs were measured with complementary DNA (cDNA) probes. The S26 ribosomal mRNA was used as a control to render results independent from variations in sample concentration (21) . The lack of contamination by normal pituitary tissue was controlled by hybridization with an oligoprobe complementary to the human POMC cDNA (16) . All of the tumors in which hybridization with this probe yielded a positive signal were excluded from our series. A human cDNA coding for the G s ␣ short isoform and cloned in PT7-7 in the ClaI site was provided by Dr. Juan Codina (Baylor College of Medicine, Houston, TX). One cDNA fragment (1.3 kb) was generated by NcoI/HindIII digestion and used as a probe. The probes specific for human SSTR2 (22) and S26 were provided by Dr. L. Ouafik (Institute Jean-Roche, Marseille, France), and the probe for human GH was provided by Dr. J. Martial (Chemistry Institute B6, University of Liege, Liege, Belgium). Pit-1 mRNA was identified using a Pit-1 human cDNA probe generated by PCR from a normal pituitary and spanning the entire coding region (20) . Human cDNA probe specific to G i2 ␣ mRNAs was obtained by RT-PCR from normal human pituitary tissue. The PCR was performed using Goldstar DNA polymerase (Eurogentec, Seraing, Belgium) at 55 C annealing temperature with a set of primers chosen according to the published sequence (23) in a specific region, not containing homologous sequence to other ␣-subunits of G protein (5Ј-CGCTCTAAGATGATCGACAAGAACCTG-3Ј and 5Ј-AGAAGAGGC-CGCAGTCCTTCAGGTTGT-3Ј). The PCR product was of the expected size (1024 bp) and was confirmed by restriction analysis using the enzymes StuI and BamHI that gave DNA fragments corresponding to the specific sequence of G i2 ␣. All of the cDNA probes were labelled with [␣-32 P]deoxy (d)-CTP using the T7 Quick-Prime kit (Pharmacia, St. Quentin en Yvelines, France). Prehybridization was performed at 42 C for 4 h in 50% formamide, 6 ϫ SSC (standard saline citrate), 5 ϫ Denhardt's solution, 0.5% SDS, and 100 g/mL denatured salmon sperm DNA. Hybridization was performed in the same buffer for 16 h at 42 C, and the blots were washed at 60 C with 0.1 ϫ SSC-0.1% SDS. Hybridization buffer (1 ϫ 10 6 cpm/mL) was used for G s ␣, GH, and S26 hybridizations, and 2 ϫ 10 6 cpm/mL were used for SSTR2, Pit-1, and G i2 ␣. To obtain complete decay of the radioactive signal, a period of 2 weeks was allowed between two consecutive hybridizations; the blots were conserved at Ϫ20 C. The blots were successively hybridized with G s ␣ or SSTR2 and GH cDNA probes, stripped, hybridized with Pit-1 and S26 cDNA probes, stripped again, and hybridized with the G i2 ␣ cDNA probe. The ␤ emission from 32 P of the cDNA probes hybridized on the blot was directly measured in counts per mm using the GS 363 Molecular Imager apparatus (Bio-Rad Laboratories, Inc., Richmond, CA) and Molecular Analyst software. Preliminary assessment of the signal intensity indicated that blots should be exposed in a phosphor screen for 2 days for the SSTR2, Pit-1, and G i2 ␣ probes, overnight for the G s ␣ and S26 probes, and for 3 h for the GH probe. The amounts of mRNA of all examined genes were rated to the amount of S26 mRNA measured on the same blot in each lane. The tumors presented in the Figs. 1 and 4 were chosen haphazardly according to the availability of the frozen tissue.
Statistical analysis
The percentages of secretory responses are presented as the mean Ϯ se. The statistical significance between two unpaired groups was determined by the Mann-Whitney test. To measure the strength of association between pairs of variables without specifying dependency, Spearman's rank order correlations were run.
Results
The gsp mutation and expression of G s ␣, Pit-1, G i2 ␣, and GH genes
Evaluation of the expression of genes coding for G s ␣, Pit-1, G i2 ␣, and GH was performed on the 24 somatotroph adenomas by Northern blot. The hybridization with Pit-1 cDNA probe showed two transcripts, one major at 2.4 kb and one minor at 4.5 kb. Quantitative analysis was performed on the major transcript (16) . As previously reported (24, 25) , the transcripts of G s ␣ and G i2 ␣ were detected in all tumors at about 1.9 and 2.3 kb, respectively. A variable expression of mRNAs corresponding to these genes was found. An example is shown in Fig. 1 for 16 somatotroph adenomas, grouped according to the presence or absence of the gsp mutation. With reference to S26 mRNA, G s ␣ mRNA levels were significantly lower in the gspϩ tumors than in the gspϪ tumors (P Ͻ 0.01; Figs. 1 and 2 ). Some gspϪ adenomas (tumors A9, A16, A17, and A18) contained very high amounts of G s ␣ mRNA. The levels of G i2 ␣ and Pit-1 mRNAs were not significantly different in the groups (Fig. 2) . Expression of the GH gene was high and variable, but related neither to the presence of the gsp oncogene (P Ͼ 0.5) nor to the in vivo and in vitro GH secretion (data not shown).
Correlations of expression of G s ␣, G i2 ␣, and Pit-1 genes
A positive correlation was found between the levels of the mRNAs for both G s ␣ and G i2 ␣ (r ϭ 0.64; P Ͻ 0.0023; Fig. 3A) , on the one hand, and the mRNAs for G s ␣ and Pit-1 (r ϭ 0.57; P Ͻ 0.0061; Fig. 3B ), on the other hand. In the same way, G i2 ␣ mRNA levels were positively correlated to those of Pit-1 mRNA (r ϭ 0.7; P Ͻ 0.0008; Fig. 3C ). No significant correlation was found between GH mRNA content and all of the other examined messengers (data not shown). An example of the Northern blot analysis is shown in Fig. 4 for 14 somatotroph adenomas classified according to their G s ␣ mRNA levels.
Octreotide sensitivity and expression of SSTR2, G i2 ␣, and Pit-1 genes
An in vivo acute octreotide test was performed before any treatment in 17 of 24 acromegalic patients. The maximal percentage of octreotide-induced inhibition of plasma GH levels varied from 0 to Ϫ97% (Table 1 ). In 16 of 24 tumors available for cell culture studies, the maximal inhibitory effects of octreotide (10 Ϫ8 mol/L for 24 h) on GH release varied from Ϫ10% to Ϫ96% (Table 1) . A positive correlation (r ϭ 0.7; P Ͻ 0.04) was observed when the in vivo and the in vitro octreotide-induced inhibition of GH secretion was analyzed. Northern blot analysis of SSTR2 was performed on 18 somatotroph adenomas (5 gspϩ and 13 gspϪ) classified according to their variable octreotide sensitivities (Fig. 5) . The blot showed a transcript of about 2.3 kb. The quantity of SSTR2 mRNA reported to S26 mRNA appeared highly variable. A significant correlation was found between the expression of SSTR2 mRNA and the percentage of octreotideinduced GH inhibition in vitro (n ϭ 12; r ϭ 0.67; P Ͻ 0.025; Fig. 6 ) as well as in vivo (n ϭ 15; r ϭ 0.7 P Ͻ 0.007; data not shown). SSTR2 mRNA was not significantly more expressed in the 5 gspϩ tumors than in the 13 gspϪ (P Ͻ 0.4). Moreover, among the tumors used for cell culture studies, the SSTR2 mRNA level was not different between the groups (P Ͻ 0.45) despite the fact that the in vitro octreotide-induced inhibition of GH secretion was significantly higher in the 5 gspϩ tumors (Ϫ63 Ϯ 7%) than in the 7 gspϪ (Ϫ30 Ϯ 9%; P Ͻ 0.028). In contrast to SSTR2 mRNAs, the expression of G i2 ␣ and Pit-1 did not appear to be correlated with octreotide sensitivity either in vivo or in vitro (data not shown). Nevertheless, a significant correlation was found between the messengers of SSTR2 and G i2 ␣ (r ϭ 0.55; P Ͻ 0.02) as well as those of SSTR2 and Pit-1 (r ϭ 0.6; P Ͻ 0.01; data not shown).
Discussion
This study clearly shows that GH-secreting adenomas bearing the gsp oncogene display a lower expression of the gene coding for G s ␣. This result is partially contradictory with one study founded only on a semiquantitative immunocytochemical analysis of the G s ␣ protein (26) . Another study, based on semiquantitative RT-PCR, has shown that the level of G s ␣ mRNA was not different in the two groups; nevertheless, the same researchers found a difference when G s ␣ protein content was considered (27, 28) . Arginine 201 of the G s ␣ subunit is the target for cholera toxin. The toxin mimics the gsp mutation, and in the mammosomatotroph GH 3 cell line, it decreases the expression of both G s ␣ protein and messenger (29) . In the S49 line, the stimulation of adenyl cyclase by forskolin induces a decrease in both G s ␣ mRNA and protein (30) . The low level of G s ␣ mRNA in gspϩ somatotroph tumors suggests the existence of a negative compensatory feedback exerted by the mutated G s ␣ protein on the expression of its own mRNA. Another compensatory adaptation to the G s ␣ mutation has been recently described FIG. 2 . Comparison of G s ␣, G i2 ␣, and Pit-1 mRNA expression levels between gspϩ and gspϪ somatotroph adenomas. The quantification of G s ␣, G i2 ␣, and Pit-1 mRNAs was performed directly on Northern blot using Molecular Imager apparatus. Measurements were reported to the level of S26 ribosomal mRNA. The mean values of the ratios of the signal intensity of G s ␣, G i2 ␣, and Pit-1 mRNAs, respectively, over the signal intensity of S26 mRNA are indicated by the horizontal lines. Significance were determined using the Mann-Whitney test.
by Lania and co-workers (31) . These researchers showed an increased phopshodiesterase activity in gspϩ tumors, which could at least in part counterbalance the constitutive activation of the cAMP-dependent pathway. These two phenomena, by preventing the functional alterations induced by G s ␣ mutated protein, may be responsible for the large clinical phenotype overlapping observed when gspϩ and gspϪ tumors are compared (4 -6, 8, 9) . Another hypothesis explaining the lack of clear-cut differences in the clinical phenotype of these two categories of tumors is supported by the high expression of G s ␣ gene observed in some gspϪ tumors. Bertherat et al. (32) have already shown that in GH tumoral cells, high levels of wild-type G s ␣ protein may promote cAMP response element (CRE)-binding protein phosphorylation. In the HEK 293 cell line derived from human embryonic kidney cells, overexpression of the wild G s ␣ protein or the expression of the mutated protein are both able to induce activation of cAMP pathway (33) . Furthermore, in somatotroph adenomas, gsp oncogene induces a variable degree of resistance to GHRH (7, 34) ; in fact, the increased expression of G s ␣ protein could have a stronger impact than the mutation itself on the intensity of the response (26) . Tumorigenesis could therefore be induced by either gsp mutation or G s ␣ overexpression, both leading to constitutive activation of the cAMPdependent pathway.
Conversely, we have not found any difference between gspϩ and gspϪ tumors concerning the messengers for G i2 ␣, Pit-1, and GH. Our data are different from those obtained from murine pituitary GH 3 or GC cell lines transfected with mutant or wild G s ␣ genes (10, 11, 32) . In these cells, the G s ␣ mutated protein was able to induce a stronger activation of the rat Pit-1 and GH promoter through the two CRE sites (11, 32) . However, concerning regulation of gene expression, it must be pointed out that important differences exist between rodents and humans; the human Pit-1 promoter does not contain CRE and is also very weakly regulated by the cAMP pathway (35) . Concerning GH mRNA and gsp oncogene, a slight difference in GH secretion was reported between gspϩ and gspϪ tumors in vivo (6) and in vitro (31) . Moreover, we did not find a correlation between the levels of GH secretion   FIG. 3 . Correlation among G s ␣, G i2 ␣, and Pit-1 mRNA expression in gspϩ (F) and gspϪ (E) somatotroph adenomas. The quantification of G s ␣, Pit-1, and G i2 ␣ mRNAs was performed directly on Northern blot using Molecular Imager apparatus. Measurements were rated to the expression level of S26 ribosomal mRNA. Correlations were assessed using Spearman's rank test .   FIG. 4 . Northern blot analysis of the expression of genes coding for G s ␣, Pit-1, G i2 ␣, and GH in 14 somatotroph adenomas, haphazardly selected among the analyzed tumors and grouped according to their G s ␣ mRNA levels. Northern blot was hybridized successively with G s ␣, Pit-1, G i2 ␣, GH, and S26 ribosomal cDNA probes and washed under high stringency. The exposure time of the blot on the phosphor screen was overnight for the G s ␣ and S26 probes, 2 days for the Pit-1 and G i2 ␣ probes, and 3 h for the GH probe.
and GH gene expression. The lack of correlation could be expected in pituitary adenomas, as GH levels are the result of complex regulatory mechanisms concerning secretory steps not directly related to the expression of hormone mRNA. These mechanisms could be altered in adenomas, as in the clinically silent somatotroph adenomas (36) .
In a previous study, Greenman et al. (37) showed that two patients expressing SSTR2 mRNA have a good in vivo octreotide response. Our results show a clear correlation between the sensitivity in vivo and in vitro to octreotide and the expression level of the SSTR2 subtype. Our finding are in agreement with studies showing a diminished binding of both radioactive SRIF and octreotide in resistant adenomas (38, 39) . As is the case for the gsp mutation (6), assessment of the expression of SSTR2 gene could also be considered a clue to the capacity of the tumor to respond to the somatostatin analog. Despite a better octreotide sensitivity of gspϩ adenomas, SSTR2 mRNA was not different in the two categories of tumors. This fact suggests that the gsp oncogene does not proceed through the increase in SSTR2 gene expression to improve the sensitivity. SSTR5 is probably also important in regulating GH secretion by somatostatin agonist (40) . It would be interesting to compare SSTR5 mRNA expression between gspϩ and gspϪ tumors. Postreceptor alterations could also be implicated in the loss of sensitivity, as was suggested by Bertherat et al. (41) . In the S49 cell line, activation of cAMP triggered by the ␤-adrenergic agonists leads to enhancement of the somatostatin inhibition due to the increment in both G i2 ␣ protein and mRNA (30) . However, we have not found any correlation between the expression of postreceptor factors, such as G i2 ␣ and Pit-1 genes, and the sensitivity to the octreotide in somatotroph adenomas. The difficulties of assessing how these factors modify sensibility come from the fact that somatostatin agonists activate more than one SSTR isoform to run more than one transduction pathway.
The expression of G i2 ␣ and Pit-1 genes was positively correlated with those of SSTR2. Moreover, correlations were found between the expression of G i2 ␣, Pit-1, and G s ␣ genes. Some of these correlations have been previously shown in the S49 cell line (30) . In human somatotroph adenomas, Hamacher and co-workers (26) found a correlation between the proteins G s ␣ and G i2 ␣. Transfected in the GH 3 cell line, G s ␣ is able to stimulate expression of the Pit-1 gene (11, 32) . The correlations found between the expression of these genes, all coding for proteins implicated in the processes of differentiation and secretion of somatotroph cells, strongly suggest a concerted genic dysregulation, which could lead to the phenotypical dedifferentiation present in these tumors.
It is most likely that pituitary tumorigenesis takes place in two steps, initiation and promotion (42) . The gsp oncogene could be considered an initiating factor. However, cells bearing the gsp oncogene are able to develop some mechanisms to counteract the disturbances induced by the G s ␣ mutation, thus restricting its phenotypical impact. The coordinated loss of expression of certain genes may activate the process of tumoral promotion. The diminished sensitivity to octreotide may represent one step in the dedifferentiation drift, as an altered response results at least in part from the impaired expression of SSTR2 mRNA. However, improvement of the sensitivity associated with the gsp oncogene seems to proceed in a way different from SSTR2 expression. FIG. 5 . Northern blot of SSTR2 gene expression in 18 somatotroph adenomas grouped according to increasing sensitivity to the octreotide. The Northern blot was hybridized successively with SSTR2 and S26 cDNA probes and washed under high stringency. The blot was exposed on a phosphor screen for 2 days for the SSTR2 probe and overnight for the S26 probe.
FIG. 6.
Comparison of the in vitro octreotide sensitivity and the expression of SSTR2 mRNA in five gspϩ (F) and seven gspϪ tumors (E). The quantitation of SSTR2 mRNA was performed directly on Northern blot using a Molecular Imager apparatus. Measurements were reported to the expression level of S26 ribosomal mRNA. The in vitro octreotide sensitivity was evaluated by octreotide (10 Ϫ8 mol/L)-induced GH inhibition for 24 h. Correlation was assessed using Spearman's rank test.
